Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 27, 2026 16:05 ET | Source: Relay Therapeutics, Inc.

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June

CAMBRIDGE, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies...
May 20, 2026 20:21 ET | Source: Relay Therapeutics, Inc.

Relay Therapeutics Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies...
May 19, 2026 16:03 ET | Source: Relay Therapeutics, Inc.

Relay Therapeutics Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies...
May 19, 2026 06:00 ET | Source: Relay Therapeutics, Inc.

Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies

Promising initial efficacy data with 60% volumetric response rate across doses and 29%* at the lowest tested dose of 100mg twice daily (BID) with all patients ongoing Interim investigator- and...
May 05, 2026 16:05 ET | Source: Relay Therapeutics, Inc.

Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates

FDA Breakthrough Therapy designation granted to zovegalisib for PIK3CA-mutant, HR+/HER2- advanced breast cancer, the Phase 3 ReDiscover-2 trial population in 2L breast cancer Presented zovegalisib...
April 29, 2026 16:05 ET | Source: Relay Therapeutics, Inc.

Relay Therapeutics to Announce First Quarter 2026 Financial Results and Corporate Highlights on May 5, 2026

CAMBRIDGE, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing...
April 27, 2026 06:00 ET | Source: Relay Therapeutics, Inc.

Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer

Zovegalisib + atirmociclib + AI selected as triplet regimen for frontline development Compelling efficacy and tolerability data for zovegalisib triplet in median 3L patients 44% ORR in heavily...
April 02, 2026 16:05 ET | Source: Relay Therapeutics, Inc.

Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026

CAMBRIDGE, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing...
March 16, 2026 07:00 ET | Source: Relay Therapeutics, Inc.

Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026

400mg BID fed is the dose used in the ongoing Phase 3 ReDiscover-2 trial, which initiated mid-2025 11.1-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic...
February 26, 2026 16:05 ET | Source: Relay Therapeutics, Inc.

Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones

Initial Phase 1 data of zovegalisib in PIK3CA-driven vascular anomalies expected to be announced in first half of 2026 Breast cancer triplet data and frontline Phase 3 plans expected to be announced...